Phase 3
Completed N=340
Prophylactic Ivermectin in COVID-19 Contacts
Source: ClinicalTrials.gov NCT04422561 ↗Enrolled (actual)
340
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath) — 15; 59 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms & diagnosis of COVID -19
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath) |
15; 59 | — |
| SECONDARY Development of COVID |
— | — |
Eligibility Criteria
Inclusion Criteria
family contact of confirmed COVID-19 case
Exclusion Criteria
- refuse to participate and receive the drug pregnancy or lactation known hypersensitivity to ivermectin
Data sourced from ClinicalTrials.gov (NCT04422561). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.